Other Major Cardiovascular Procedures with MCC DRG Reimbursement

Summary & Overview

Other Major Cardiovascular Procedures with MCC: Inpatient Reimbursement Overview

DRG 270 encompasses major non-coronary cardiovascular procedures with a Major Complication or Comorbidity, covering complex valve, thoracic aortic, and other high-acuity intrathoracic cardiac operations. It matters for inpatient reimbursement because assignment to this Diagnosis-Related Group recognizes substantially higher resource needs and results in higher Medicare payments compared with lower-severity groupings.

Other Major Cardiovascular Procedures with Major Complication or ComorbidityDRG Other Major Cardiovascular Procedures with MCCDRG 270Diagnosis-Related GroupInpatient ReimbursementMedicareCardiac SurgeryCardiothoracic SurgeryValve ProceduresAortic Repair

DRG 270 Overview

DRG 270 covers hospital admissions for major cardiovascular procedures other than coronary artery bypass that are accompanied by a Major Complication or Comorbidity, such as complex valve operations, thoracic aorta repairs, or other high-risk intrathoracic cardiac procedures. This Diagnosis-Related Group signals high resource use, extended operative and postoperative care, and greater expected intensity of services. For Medicare payment, classification to DRG 270 typically yields higher inpatient reimbursement to reflect the increased clinical complexity and costs. Accurate coding of procedures and comorbidities directly affects placement in this Diagnosis-Related Group and subsequent payment.

National Payment Rates

Across commercial payers the observed rate range for DRG 270 spans roughly from $1.1K (BCBS p25) up to $180K (Anthem max), with the widest payer spread seen between Anthem (max $180K) and BCBS (min $370/$1.1K region), reflecting substantial variability across payers. See the table and chart below for payer-level percentiles and distribution details. Individual payer medians (Anthem $81K, Cigna $80K, Aetna $77K, BCBS $46K) highlight differences in central tendency across commercial plans.

Mean Rates by Payer — National — DRG 270

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Payer rates in Alaska for DRG 270 range from $82K to $130K across observed payers, with Blue Cross Blue Shield at the low end and Anthem at the high end. The most notable deviation from national averages is Anthem’s mean of $130K, which sits well above typical national means for this DRG. See the table and chart below for payer-specific distributions.

Key Insights for Alaska

Anthem is the highest-paying payer in Alaska at $130K (mean), while BCBS and Blue Cross Blue Shield are the lowest at $82K (mean).
Alaska’s payer range spans from $82K to $130K, with Anthem notably above national means for several payers, indicating higher regional ceilings compared with typical national rates.

Clinical Trials

Acute procedural optimization trials investigating novel intraoperative techniques or adjunctive technologies for complex cardiovascular surgeries (for example, studies assessing strategies to reduce cardiopulmonary bypass time, myocardial protection approaches, or adjunct imaging guidance during reoperative or anatomically challenging procedures). These studies enroll high-acuity inpatients undergoing major non-standard cardiovascular operations included in this DRG, often with significant comorbidity or prior cardiac surgery, and measure perioperative morbidity, organ dysfunction, and short-term mortality. Results are directly relevant to surgeons, intensivists, and hospital finance teams because improved procedural safety and reduced complications can shorten ICU and total length of stay and decrease costly major complication rates that drive higher reimbursement under this DRG.
Comparative effectiveness studies evaluating surgical versus hybrid or less invasive alternatives for complex cardiovascular indications (for example, head-to-head evaluations of open surgical approaches compared with hybrid endovascular-plus-surgical strategies or staged procedures in patients with multilevel disease or redo operations). These trials target heterogeneous inpatient cohorts captured by this DRG who have anatomy or comorbidity profiles that make the optimal approach uncertain; endpoints include complication rates, need for reintervention, functional recovery, and resource utilization. Payers and hospital administrators use this evidence to inform pathway selection, bundle pricing, and case-mix planning because differences in complication patterns and downstream resource use materially affect reimbursement and total cost of care for DRG 270 cases.
Post-discharge outcomes and readmission reduction studies focused on multimorbidity management and transition-of-care interventions after complex cardiovascular procedures (for example, randomized or pragmatic trials of coordinated discharge bundles, intensive early outpatient surveillance, or medication reconciliation and rehabilitation programs in patients with heart failure, renal dysfunction, or frailty who underwent major cardiovascular operations). These studies enroll survivors of inpatient stays classified under this DRG and measure 30- to 90-day readmissions, outpatient resource use, patient-reported outcomes, and downstream costs. Findings are important to clinicians and payers because preventing readmissions and functional decline after high-risk procedures can reduce penalties, lower total episode costs, and improve value for a population that drives substantial inpatient spending under this DRG.

Related Codes

296-CARDIAC-ARREST-UNEXPLAINED-WITH-MCC

Cardiac Arrest, Unexplained with Major Complication or Comorbidity: Inpatient Reimbursement Overview

261-CARDIAC-PACEMAKER-REVISION-EXCEPT-DEVICE-REPLACEMENT-WITH-CC

Cardiac Pacemaker Revision Except Device Replacement with CC: Inpatient Reimbursement Overview

258-CARDIAC-PACEMAKER-DEVICE-REPLACEMENT-WITH-MCC

Cardiac Pacemaker Device Replacement with MCC: Inpatient Reimbursement Overview

209-COMPLEX-AORTIC-ARCH-PROCEDURES

Complex Aortic Arch Procedures: Inpatient Reimbursement Overview

244-PERMANENT-CARDIAC-PACEMAKER-IMPLANT-WITHOUT-CC-MCC

Permanent Cardiac Pacemaker Implant without CC/MCC: Inpatient Reimbursement Overview

212-CONCOMITANT-AORTIC-AND-MITRAL-VALVE-PROCEDURES

Concomitant Aortic and Mitral Valve Procedures: Inpatient Reimbursement Overview

274-PERCUTANEOUS-AND-OTHER-INTRACARDIAC-PROCEDURES-WITHOUT-MCC

Percutaneous and Other Intracardiac Procedures without MCC: Inpatient Reimbursement Overview

266-ENDOVASCULAR-CARDIAC-VALVE-REPLACEMENT-AND-SUPPLEMENT-PROCEDURES-WITH-MCC

Endovascular Cardiac Valve Replacement and Supplement Procedures with MCC: Inpatient Reimbursement Overview

288-ACUTE-AND-SUBACUTE-ENDOCARDITIS-WITH-MCC

Acute and Subacute Endocarditis with MCC: Inpatient Reimbursement Overview

233-CORONARY-BYPASS-WITH-CARDIAC-CATHETERIZATION-OR-OPEN-ABLATION-WITH-MCC

Coronary Bypass with Cardiac Catheterization or Open Ablation with MCC: Inpatient Reimbursement Overview

Showing 1–10 of 100

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

OpenPayer

Summary & Overview

Other Major Cardiovascular Procedures with MCC: Inpatient Reimbursement Overview

DRG 270 Overview

National Payment Rates

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes